Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia
May 2021
in “
Molecules
”
Studysummary This study found that men with early-onset androgenetic alopecia may experience less benefit from rosuvastatin treatment in terms of improving cardiometabolic risk factors compared to men with normal hair growth.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on mdpi.com →